This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Inadvertent Effects of Drugs in Clinical Practice

Yaakov Henkin, MD; Jackson A. Como, PharmD; Albert Oberman, MD

JAMA. 1992;267(7):961-968.

Abstract
Objective.
—To examine the available literature on commonly prescribed drugs and their effects on blood lipid and lipoprotein levels.

Data Sources.
—The review was based on searches of English-language articles from 1975 to 1990 by Medlars II and MEDLINE programs, the Index Medicus for 1980 to 1990, and references from identified articles. Relevant journals published within the last 6 months were also examined.

Study Selection.
—More than 500 articles were identified for inclusion. Articles were selected on the basis of appropriateness of design to demonstrate significant results, determined by consensus when necessary.

Data Extraction.
—Studies were classified according to type (observational or interventional), length of follow-up, and type of controls. Quanitative analysis of lipid, lipoprotein, and apoprotein changes induced by drugs was computed as the percentage of change observed during the course of the study (interventional) or compared with the controls at a given time (observational).

Data Synthesis.
—Steroid hormones that have strong progestogenic and androgenic properties, retinoids, cyclosporine A, and phenothiazines are potentially atherogenic. Steroid hormones with dominant estrogenic properties, several anticonvulsants, biguanides, high-dose ketoconazole, and aminosalicylic acid are potentially antiatherogenic. Corticosteroids appear to elevate all the lipoprotein cholesterol levels. Oral estrogens, retinoids, and corticosteroids also can elevate triglyceride levels. Other drugs with questionable effects on lipoprotein metabolism are reviewed.

Conclusion.
—Although the long-term implications of drug-induced lipoprotein changes are still undefined, physicians need to consider these effects in clinical practice.

(JAMA. 1992;267:961-968)

Author Affiliations
From the Division of General and Preventive Medicine (Drs Henkin and Oberman) and the Department of Pharmacy (Dr Como), University of Alabama at Birmingham.

Footnotes
Reprint requests to Division of General and Preventive Medicine, University of Alabama at Birmingham, UAB Station, Medical Education Bldg, Room 621, Birmingham, AL 35294 (Dr Oberman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Role of an Intravenous Fat Emulsion Composed of Fish Oil in a Parenteral Nutrition-Dependent Patient With Hypertriglyceridemia
Gura et al.
Nutr Clin Pract 2007;22:664-672.
ABSTRACT | FULL TEXT  

A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men
May et al.
Int J Epidemiol 2007;36:1309-1318.
ABSTRACT | FULL TEXT  

Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients
Sachet et al.
Lupus 2007;16:273-278.
ABSTRACT  

Effect of Raloxifene on Serum Triglycerides in Women With a History of Hypertriglyceridemia While on Oral Estrogen Therapy
Carr et al.
Diabetes Care 2005;28:1555-1561.
ABSTRACT | FULL TEXT  

Dyslipemia in Familial Partial Lipodystrophy Caused by an R482W Mutation in the LMNA Gene
Schmidt et al.
J. Clin. Endocrinol. Metab. 2001;86:2289-2295.
ABSTRACT | FULL TEXT  

The Endocrine Effects of Nonhormonal Antineoplastic Therapy
Yeung et al.
Endocr. Rev. 1998;19:144-172.
ABSTRACT | FULL TEXT  

Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies
Borba and Bonfa
Lupus 1997;6:533-539.
ABSTRACT  

Cholesterol Screening: Once Is Not Enough
Wilson
Arch Intern Med 1995;155:2146-2147.
ABSTRACT